You are here

Conclusion and Further Reading - Chapter 12

Chapter 12 - Breast Cancer in the Senior Patient

Conclusion

There is increasing evidence that a selected population of elderly breast cancer patients may benefit from specific anticancer therapies both in the adjuvant and metastatic settings. Data supporting adjuvant chemotherapy or trastuzumab in unfit patients are lacking, and the benefit of adjuvant endocrine therapy in unfit patients or older patients at very low risk of relapse is uncertain. A personalised approach that takes into account the tumour and the patient’s characteristics (e.g., tumour burden, presence of symptoms), as well as patient’s preferences, should be considered in unfit patients with advanced disease. The patient’s age should not limit access to new treatment options. However, it is difficult to translate the results of trials conducted in selected patients to the overall older adult population, especially to those with comorbidities and increased susceptibility to adverse events.

Further Reading

« Previous Page Next Page »